Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 1, 2008

Lonza Reports Manufacturing Deal with Osiris and Facility Constructions

  • Lonza signed a clinical and commercial manufacturing agreement with Osiris Therapeutics for Prochymal®, Osiris’ adult stem cell therapy. Prochymal is being evaluated in Phase III trials for acute and steroid-refractory graft-versus-host disease and Crohn's disease.

    Lonza also announced the construction of new facilities including the first commercial-scale allogeneic cGMP manufacturing plant and additional capacity to produce cGMP-grade cell culture media for therapeutic applications. This will provide Lonza the capacity to manufacture the tens of billions of cells per day needed to support its clients’ commercialization efforts, say Lonza officials.



Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »